Product Information
MESALAMINE 800 MG DR TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $4.0205 per EA under NDC 00480775080. Its NADAC has been published 106 times since Sep 25, 2024.
FDA first approved this application on Aug 22, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
800 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480775080
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA213191FDA Approved
8/22/2024
TE Code
AB
On Market Since
8/22/2024
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE 800 MG DR TABLET has been published 106 times since Sep 25, 2024, and over the history we have for it it has declined 29.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.0205 per EA |
|---|---|
| All-time high | $5.8207 (Nov 13, 2024) |
| All-time low | $4.0027 (Aug 19, 2026) |
| 52-week high | $4.7363 |
| 52-week low | $4.0027 |
| Median price | $4.5352 |
| Average price | $4.7976 |
| Largest weekly change | -8.2% (Jun 18, 2025) |
| Weeks tracked | 106 |
| Tracking since | Sep 25, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE 800 MG DR TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE 800 MG DR TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $4.0205 per EA (NDC 00480775080), effective Sep 30, 2026.
How has the price of MESALAMINE 800 MG DR TABLET changed over time?
Over the history we have for it, the NADAC for MESALAMINE 800 MG DR TABLET has declined 29.7%. It has been tracked across 106 weekly CMS publications since Sep 25, 2024.
What are the highest and lowest recorded NADAC prices for MESALAMINE 800 MG DR TABLET?
Since Sep 25, 2024, the NADAC for MESALAMINE 800 MG DR TABLET has ranged from a low of $4.0027 (Aug 19, 2026) to a high of $5.8207 (Nov 13, 2024), with a median of $4.5352 per EA.
Are there cheaper alternatives to MESALAMINE 800 MG DR TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MESALAMINE 800 MG DR TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures MESALAMINE 800 MG DR TABLET?
MESALAMINE 800 MG DR TABLET (NDC 00480775080) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.